Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com -- Fujifilm Holdings reported strong first-quarter results for fiscal year 2026 on Wednesday, with operating profit reaching ¥75.3 billion, up 21.1% year-over-year and exceeding market expectations.
The company achieved record first-quarter sales of ¥749.4 billion, a slight 0.1% increase from the previous year, though this represents a 4.5% gain when excluding foreign exchange effects. Operating profit surpassed the company’s internal outlook by approximately ¥7-8 billion.
In the Healthcare segment, sales declined 2.9% to ¥228.5 billion, though they increased 1.6% when excluding currency effects. The Bio-CDMO business showed strong performance with sales of ¥53.2 billion, up 12.8% year-over-year, supported by first-phase investments in Denmark and recovery at the Texas site.
Fujifilm reported significant progress in securing contracts for its expanding CDMO facilities. The company finalized a contract for one system under the Denmark second-phase project and is close to finalizing contracts for three of four systems planned for fiscal year 2027. For its U.S. second-phase expansion starting in fiscal year 2029, Fujifilm has secured long-term contracts with multiple major drug firms for half of the planned systems.
The Electronics segment saw sales of ¥102.1 billion with operating profit of ¥22.5 billion, driven by strong semiconductor materials performance. The Imaging division posted impressive results with sales of ¥145.3 billion and operating profit of ¥41.8 billion, representing substantial growth when excluding currency effects.
Despite potential tariff impacts estimated at ¥6.0 billion, Fujifilm maintained its full-year guidance for fiscal year 2026, targeting sales of ¥3,280.0 billion and operating profit of ¥331.0 billion.
Jefferies analysts noted that Fujifilm "posted resilient results amid uncertainty in the external environment."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.